Nové možnosti nákladné pneumoonkologické léčby pokročilého nemalobuněčného karcinomu plic (NSCLC) v první linii dle morfologické a molekulárně genetické diagnostiky v České republice
| Title in English | New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the first line based on morphological and molecular genetic diagnosis in the Czech Republic |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.onkologiecs.cz/pdfs/xon/2012/02/08.pdf |
| Field | Oncology and hematology |
| Keywords | non-small-cell lung carcinoma (NSCLC); diagnosis; treatment of advanced NSCLC; biological therapy; pemetrexed |
| Description | Current diagnosis of non-small-cell lung carcinoma (NSCLC) cannot rest merely on the determination that it is NSCLC without providing any further specification. Accurate morphological classification of NSCLC and classification into individual subtypes (adenocarcinoma, large-cell carcinoma, squamous-cell carcinoma…) as well as genetic testing are all required. When the morphological and molecular genetic diagnosis has been accurately established, patients with NSCLC can receive agents whose efficacy, while meeting certain criteria, offers a chance of improved survival. They include both drugs from the cytostatic group and those for biologically targeted therapy. The paper deals with those agents for which the amount of reimbursement for the first-line treatment of NSCLC has been determined in the Czech Republic. They are bevacizumab, pemetrexed and gefitinib. |